ISIN:DE000A1EWVY8

DGAP-News: Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207

Tuesday, October 19, 2021 - 6:01am

Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).

Key Points: 
  • Under the terms of the agreement, SCG has access to Formycon's ACE2 fusion protein technology and has acquired an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific (APAC) region (except Japan).
  • The APAC region is home to about 60% of the world's population and is the world's second largest healthcare market.
  • SCG will be responsible for the development and manufacturing of FYB207 in Asia, and if approved, bring this innovative COVID-19 drug to patients and healthcare providers in the Asia-Pacific region."
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.

DGAP-News: Formycon Reports on Virtual Annual General Meeting 2021

Monday, September 27, 2021 - 4:09pm

Press Release // September 27, 2021

Key Points: 
  • Press Release // September 27, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its Annual General Meeting on September 27, 2021 - for the protection of all persons involved - in virtual form.
  • The shareholders were able to follow the virtual Annual General Meeting live in picture and sound via the Company's AGM portal.
  • They followed the proposals of the Management Board and Supervisory Board and approved all the resolutions proposed by the management with large majorities.
  • Voting rights could be executed before and during the virtual Annual General Meeting by postal vote or by authorizing the Company's proxies.

DGAP-News: Formycon Publishes Half-Year Results for 2021

Tuesday, September 21, 2021 - 7:01am

Press Release // September 21, 2021

Key Points: 
  • Press Release // September 21, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today announced its financial results for the first half of 2021.
  • On the day of reporting, June 30, 2021, the Formycon Group's financial figures were as forecast.
  • For the full year of 2021, Formycon forecasts revenues above last year's level for the entire Group (2020: Euro 34.2 million).
  • Following the successful approval of these products, Formycon will also take a share of subsequent commercialization revenues.

DGAP-News: Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021

Wednesday, September 15, 2021 - 8:01am

Press Release // September 15, 2021

Key Points: 
  • Press Release // September 15, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB207.
  • For what is now the 22nd time, the Pharma Trend Image & Innovation Awards, also known in the industry as the Pharma Oscars, were presented in various categories at a celebratory awards ceremony under the patronage of Bavarian Health Minister Klaus Holetschek, MdL.
  • "Receiving the prestigious Pharma Trend Image & Innovation 'Most Innovative Product(R)' Award for Leap Innovations is a great pleasure and encourages us in our innovative COVID-19 drug development.
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of an innovative COVID-19 drug.

DGAP-News: Formycon reports on the status of FYB207 development

Wednesday, August 11, 2021 - 3:19pm

Press Release // August 11, 2021

Key Points: 
  • Press Release // August 11, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today provided an update on the development status of its COVID-19 drug FYB207.
  • In summary, these laboratory data demonstrate that FYB207 retains its full antiviral potential even in the rapidly spreading SARS-CoV-2 variants-of-concern.
  • Due to the expansion of preclinical testing, clinical development is expected to start in the first half of 2022.
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 fusion protein.